C. Kent Osborne

C. Kent Osborne's AcademicInfluence.com Rankings

C. Kent Osborne

Philosophy

#8527

World Rank

#11932

Historical Rank

Logic

#5559

World Rank

#6966

Historical Rank

philosophy Degrees

Download Badge

Philosophy

C. Kent Osborne's Degrees

Doctorate Medicine University of Texas Medical Branch

Why Is C. Kent Osborne Influential?

(Suggest an Edit or Addition)

(See a Problem?)

C. Kent Osborne's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. (1999) (2062)
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. (2004) (1172)
Mechanisms of endocrine resistance in breast cancer. (2011) (1018)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer (2014) (850)
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer (2003) (849)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (2003) (811)
Treatment of HER2-positive breast cancer: current status and future perspectives (2012) (767)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. (1998) (708)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. (2002) (626)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. (2008) (512)
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. (2005) (500)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. (2008) (474)
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance (2004) (446)
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. (2005) (439)
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. (1992) (421)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (2004) (398)
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis (2012) (391)
Selective estrogen receptor modulators: structure, function, and clinical use. (2000) (380)
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. (1989) (346)
ICI 182,780 (Faslodex™) (2000) (343)
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. (2003) (343)
Estrogen-receptor biology: continuing progress and therapeutic implications. (2005) (343)
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study (2000) (312)
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. (1998) (301)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase (2011) (277)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women (2003) (260)
The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. (1994) (250)
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. (2006) (248)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer (2010) (240)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers (2005) (239)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation (2011) (233)
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). (2005) (215)
An international study to increase concordance in Ki67 scoring (2015) (211)
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. (1998) (206)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. (2007) (198)
Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer (2004) (197)
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer (2013) (195)
Targeting HER2 for the treatment of breast cancer. (2015) (195)
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. (2005) (192)
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study (2011) (192)
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes (2010) (190)
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. (2003) (189)
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. (2003) (180)
Estrogen receptor: current understanding of its activation and modulation. (2001) (179)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. (2006) (166)
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. (1997) (165)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma (2005) (161)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up (2012) (158)
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial (2017) (156)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer (2014) (155)
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib (2011) (154)
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators (2005) (151)
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. (2003) (142)
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. (2010) (133)
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. (2005) (131)
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients (2008) (130)
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. (2008) (127)
Towards personalized treatment for early stage HER2-positive breast cancer (2019) (127)
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. (2000) (125)
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. (2005) (123)
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival (1996) (121)
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. (2005) (117)
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. (2009) (116)
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration (2016) (116)
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. (1994) (112)
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer (2016) (106)
Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials (2004) (101)
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance (2006) (97)
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth (2006) (96)
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. (2011) (94)
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. (1996) (92)
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. (1998) (91)
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. (1998) (85)
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
The changing role of ER in endocrine resistance. (2015) (83)
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. (1996) (81)
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. (2013) (79)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy (2015) (79)
Attribution of Blame, Self-forgiving Attitude and Psychological Adjustment in Women with Breast Cancer (2007) (75)
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer (2019) (74)
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. (2016) (72)
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients (2010) (71)
Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer (2005) (71)
Role of the Estrogen Receptor Coactivator AIB 1 ( SRC-3 ) and HER-2 / neu in Tamoxifen Resistance in Breast Cancer (2003) (68)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (66)
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. (2020) (65)
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. (1994) (61)
Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy (2003) (59)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer (2018) (59)
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. (1996) (57)
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies (2005) (57)
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (56)
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration (2019) (54)
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance (2014) (53)
Correlation of primary breast cancer histopathology and estrogen receptor content (1981) (53)
Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer (2010) (49)
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. (2017) (49)
Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial (2009) (49)
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. (1997) (48)
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. (2005) (46)
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. (1998) (46)
Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. (1989) (44)
Systemic mirnas as potential biomarkers for malignancy (2012) (43)
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy (2013) (40)
TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (2011) (40)
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). (2007) (40)
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 (2017) (37)
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. (2020) (37)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (36)
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer (2018) (36)
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance (2016) (36)
Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. (2001) (34)
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. (2015) (34)
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. (1999) (31)
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers (2005) (28)
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer (2019) (28)
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study (2017) (28)
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer (2010) (28)
Aromatase inhibitors: Future directions (2005) (27)
Amplification and over‐expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells (2014) (27)
Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer (2015) (26)
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. (2009) (26)
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (2019) (25)
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. (1997) (24)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. (1993) (24)
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. (1993) (23)
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. (2014) (23)
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. (1994) (19)
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer (2018) (18)
Adjuvant therapy of breast cancer: Southwest Oncology Group studies. (1986) (16)
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients (2013) (15)
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis (2019) (14)
HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. (2018) (14)
Breast Cancer: Blocking both driver and escape pathways improves outcomes (2012) (14)
Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2009) (13)
Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials (2001) (13)
Is There a Role for Adjuvant Tamoxifen in Progesterone Receptor–Positive Breast Cancer? An In silico Clinical Trial (2006) (13)
Aromatase inhibitor adverse effects: are we sweeping them under the rug? (2014) (11)
Breast Cancer Endocrine Resistance (2003) (11)
Chemotherapy versus observation in high-risk node-negative breast cancer patients. (1992) (11)
Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition (2014) (11)
Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients (1997) (10)
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer (2004) (8)
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil, vincristine, and prednisone compared with single‐agent L‐phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes (2003) (8)
Adjuvant combination chemotherapy cmfvp vs oophorectomy followed by cmfvp ocmfvp for premenopausal women with er positive operable breast cancer with positive axillary lymph nodes an intergroup study (1991) (8)
Molecular Mechanisms of Endocrine Resistance (2018) (7)
The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 (2016) (7)
A BRCA1-Like, 25-Gene Assay Predicts for Anthracycline-Chemosensitivity in Sporadic Triple-Negative Breast Cancer. (2009) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
Therapeutic resistance and tumor-initiation: Molecular pathways involved in breast cancer stem cell self-renewal (2007) (7)
Role of molecular and genetic markers in breast cancer treatment decisions. (2003) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
Decrease in tumorigenic breast cancer stem cells – final results of a neoadjuvant trial in primary breast cancer patients (2008) (5)
Phase III Study of Standard Combination Versus Rotating Regimen of Induction Chemotherapy in Patients With Hormone Insensitive Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Intergroup Study (E3185) (2007) (5)
Abstract 3091: A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis (2012) (5)
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. (2019) (5)
Navigator program for breast cancer trial recruitment and enrollment at a county hospital (2005) (5)
Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models (2020) (4)
Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer. (2016) (4)
New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer (2005) (4)
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. (1985) (4)
A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer (2021) (4)
PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial. (2018) (4)
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. (1989) (4)
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer (2022) (3)
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: A comparison of CMFVP versus L-PAM (1985) (3)
Advances in Brief The Small Heat Shock Protein hsp 27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines 1 (2007) (3)
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
Gene Expression Signatures of PI3K Signaling Are Associated with Low ER Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human Tumors, and in Patients Predicts Poor Outcome. (2009) (3)
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach (2022) (3)
Molecular biology (pre-clinical) (2012) (3)
BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer. (2009) (3)
Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (2018) (3)
Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer (2021) (3)
Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study (2020) (3)
Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes (2013) (3)
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer (2021) (2)
Abstract S4-01: A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models (2017) (2)
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer (2005) (2)
Abstract P4-02-01: Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study (2010) (2)
Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression. (2004) (2)
Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers (2005) (2)
Adjuvant therapy in node-negative breast cancer (1989) (2)
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status (1985) (2)
Abstract PD3-09:HER2 L755Smutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models (2021) (2)
A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue (2001) (2)
Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors (2012) (1)
Abstract SP139: HER2 targeted therapy: Determinants of response and mechanisms of resistance (2021) (1)
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications (2022) (1)
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. (2022) (1)
Abstract P4-06-02: Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer. (2012) (1)
Subtype of Breast Tumor Xenografts Transforms the Clinically Associated Molecular Profile Development of Resistance to Targeted Therapies (2008) (1)
Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells (2015) (1)
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer. (2021) (1)
Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation. (2009) (1)
Abstract 1077: Acquired neratinib resistance is associated with acquisition ofHER2andPIK3CAmutations and can be overcome using potent drug combinations in HER2-positive breast cancer models (2021) (1)
Abstract P4-04-03: Hyperactive FOXA1 activates super-enhancer-engaged HIF2α/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer (2018) (1)
Abstract OT3-02-08: Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer (2016) (1)
Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer (2021) (1)
Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 (2015) (1)
S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis (2009) (1)
P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer. (2011) (1)
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
Abstract PD2-04: FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer (2017) (1)
Triple-negative breast cancers: Biomarkers and outcomes. (2010) (1)
ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials (2019) (1)
Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines (2019) (1)
Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P). (2019) (1)
Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC). (2016) (1)
0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels (2009) (1)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (1)
Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
Mirnas: Small molecules, big players in tamoxifen resistance in breast cancer (2012) (1)
P3-03-05: Identification of miRNAs and Their Associated Target Genes Involved in Endocrine Resistance in Breast Cancer. (2011) (1)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (1)
Scalp cooling alopecia prevention trial (SCALP). (2014) (1)
Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer (2023) (0)
Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience (2022) (0)
AND ITS POTENTIAL CLINICAL APPLICATIONS (1989) (0)
Gene expression profiles in formalin-fixed, paraffin-embedded (FFPE) core biopsies predict docetaxel chemosensitivity. (2006) (0)
Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models (2019) (0)
Revised Abstract 7, 23rd annual San Antonio Breast Cancer Symposium (2004) (0)
PG 7.03 The changing role of ER in endocrine resistance (2015) (0)
Abstract CT256: A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer (2021) (0)
Breast tumor xenografts of luminal subtype switch to the ERBB2+ molecular subtype in response to endocrine therapy: Gene expression profiling may not predict pathways of resistance in pretreatment tumors (2007) (0)
Chemoprevention Breast Cancer Workshop, November 20, 1987 Panel Discussions (1988) (0)
Abstract 738: Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies (2015) (0)
Abstract PD6-02: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors (2019) (0)
Abstract 721: Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+ breast cancer (2015) (0)
Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience. (2021) (0)
Abstract P2-06-09: Mucin4 Is Associated with the Loss of Estrogen-Receptor-α in Breast Cancer (2010) (0)
Faslodex, a new pure antagonist for endocrine therapy of breast cancer (2002) (0)
Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination (2015) (0)
Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC) (2021) (0)
Abstract P5-05-01: Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance (2015) (0)
Abstract OT1-18-07: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (2022) (0)
Abstract OT-13-03: A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neupeptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer (2021) (0)
Combination antiHER therapeutics — efficacy of alternative dosing regimens in ER+/HER2+ breast cancer xenografts. (2009) (0)
Author response: Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy (2013) (0)
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis (2019) (0)
Abstract A44: Minority enrollment to clinical trials: Experience at the Dan L. Duncan Cancer Center (2010) (0)
ComprehensiveGenomicAnalysis Identi fi esNovel Subtypes and Targets of Triple-Negative Breast Cancer (2015) (0)
Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (2022) (0)
Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
Abstract 2032: Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG 8897 trial (2016) (0)
Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. (2015) (0)
Abstract S6-10: Identification of a Novel Tumor Suppressor Network Reveals a Role for Proto-Oncogenic Receptor Tyrosine Kinases in Triple-Negative Breast Cancer (2010) (0)
Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models (2022) (0)
Abstract OT2-10-06: Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 (2023) (0)
46PMetabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD) (2017) (0)
SARS ACADEMIC AND RESEARCH PRIZE: 0440: A COMPARISON OF THREE TENDON-TYING TECHNIQUES FOR USE DURING ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION (2012) (0)
Abstract P4-02-20: Plasticity of the ER and HER2 Signaling Networks Results in Compensatory Escape Pathways Contributing to Treatment Resistance (2010) (0)
P1-08-04: Obesity, Adjuvant Therapy, and Survival Outcomes in Early-Stage Breast Cancer. (2011) (0)
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (0)
Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
Abstract CT232: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 (2022) (0)
P4-07-03: Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells. (2011) (0)
P4-01-02: Endocrine Resistance: Mechanism, Tumorigenic Capacities, and New Therapeutic Strategies. (2011) (0)
Abstract 3969: CTCs and CTC clusters in breast cancer patient-derived xenograft models (2016) (0)
A gene expression signature of eventual brain metastases in patients with breast cancer (2007) (0)
Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance (2015) (0)
Characteristics of a high-risk minority population (2007) (0)
Histological grading and molecular correlates of ductal carcinoma in situ (DCIS) (1997) (0)
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis (2023) (0)
DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. (2020) (0)
SA 2.1 – Overcoming resistance to HER2 targeting agents (2017) (0)
Abstract of ASTRO scientific posters to be presented poster sessionSimultaneous chemotherapy — Radiotherapy with prophylactic irradiation foinoperable adeno and large cell lung carcinoma. A southwest oncology group pilot study (1984) (0)
Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer (2022) (0)
Abstract P2-09-08: Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance (2013) (0)
Gene signature of cancer stem cells is manifested within an intrinsic subgroup of breast cancers with mesenchymal properties (2008) (0)
Estrogen Receptor Genomic Function Factor Receptor Signaling with Repression of Classic Tamoxifen Resistance in Breast Tumors Is Driven by Growth (2008) (0)
Abstract P2-02-14: Metabolic regulation and drug resistance in c-Src activated triple negative breast cancer (2019) (0)
Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration (2018) (0)
Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data. (2016) (0)
Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling. (2013) (0)
Abstract P6-04-05: GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells (2013) (0)
Abstract P1-04-10: Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52 (2023) (0)
Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy (2017) (0)
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. (2022) (0)
Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC) (2023) (0)
Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance (2021) (0)
Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer (2020) (0)
Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models (2019) (0)
Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52 (2022) (0)
Abstract P2-23-01: Patient-derived xenografts allow deconvolution of single agent and combination chemotherapy responses in triple-negative breast cancer (2023) (0)
Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast cancer (PACT01 trial) (2019) (0)
Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. (1994) (0)
Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer (2020) (0)
Overcoming Endocrine Resistance by Targeting ER/FoxA1/IL 8 Axis (2015) (0)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer (2018) (0)
Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer (2022) (0)
ComprehensiveGenomicAnalysis IdentifiesNovel Subtypes and Targets of Triple-Negative Breast Cancer (2015) (0)
Abstract A62: PARP-1 regulates NF-κB-mediated IL-8 expression in HER2 positive breast cancer (2015) (0)
Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models (2023) (0)
Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience. (2021) (0)
Abstract S5-8: Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. (2012) (0)
Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib (2017) (0)
P4-01-03: Establishment and Characterization of an Endocrine Resistance Model In Vitro and In Vivo by Inducible PTEN Knockdown. (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With C. Kent Osborne?

C. Kent Osborne is affiliated with the following schools:

University of Texas Health Science Center at San Antonio
Inje University
Baylor College of Medicine
University of Western Australia